

LONDON ONCOLOGY CLINICAL TRIALS DIRECTORY

PHASE I STUDIES												
Cancers	Drug	Study Type	Short Name	Name of Study	NIHR adopted?	UKCRN ID	Chief Investigator	Trust	Hospital	PrincipallInvestigator	Contact	Inclusion/Exclusion
Metastatic prostate cancer	JNJ-56021927 (Androgen receptor inhibitor)	Interventional	A Drug-Drug Interaction, Safety and Efficacy Study With JNJ-56021927 (ARN-509) and Abiraterone Acetate in Subjects With Metastatic Castration-Resistant Prostate Cancer	A Drug-Drug Interaction, Safety and Efficacy Study With JNJ-56021927 (ARN-509) and Abiraterone Acetate in Subjects With Metastatic Castration-Resistant Prostate Cancer	No		Dr Gerhardt Attard	The Royal Marsden NHS Foundation Trust	Royal Marsden Hospital	Dr Gerhardt Attard	Gerhardt.Attard@rmh.nhs.uk	https://clinicaltrials.gov/ct2/show/NCT02123758
Metastatic prostate cancer	TAS3681 (androgen receptor antagonist)	Interventional	A PHASE 1, OPEN-LABEL, NON-RANDOMIZED, SAFETY, TOLERABILITY, AND PHARMACOKINETIC STUDY OF TAS3681 IN PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER	A PHASE 1, OPEN-LABEL, NON-RANDOMIZED, SAFETY, TOLERABILITY, AND PHARMACOKINETIC STUDY OF TAS3681 IN PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER	Pending		Prof Johann De Bono	The Royal Marsden NHS Foundation Trust	Royal Marsden Hospital	Prof Johann De Bono	Johann.DeBono@icr.ac.uk	https://clinicaltrials.gov/ct2/show/NCT02566772
Metastatic Castrate Resistant Prostate Cancer	BI 836845 (monoclonal antibody targeting IGF-1 and IGF-2)	Interventional	A Phase Ib/II, Multicentre, Open Label, Randomised Study of BI 836845	A Phase Ib/II, Multicentre, Open Label, Randomised Study of BI 836845 in Combination with Enzalutamide, versus Enzalutamide alone, in Metastatic Castration-Resistant Prostate Cancer (CRPC) Following Disease Progression on Docetaxel-Based Chemotherapy and Abiraterone	No		Prof Johann De Bono	The Royal Marsden NHS Foundation Trust	Royal Marsden Hospital	Prof Johann De Bono	Johann.DeBono@icr.ac.uk	https://clinicaltrials.gov/ct2/show/NCT02204072
Metastatic Castrate Resistant Prostate Cancer	GSK2636771 (PI3Kβ-selective inhibitor)	Interventional	A Phase I, Open-Label, Dose-Finding Study of GSK2636771 Administered in Combination with Enzalutamide (Xtandi) in Male Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC)	A Phase I, Open-Label, Dose-Finding Study of GSK2636771 Administered in Combination with Enzalutamide (Xtandi) in Male Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC)	No		Prof Johann De Bono	The Royal Marsden NHS Foundation Trust	Royal Marsden Hospital	Prof Johann De Bono	Johann.DeBono@icr.ac.uk	https://clinicaltrials.gov/ct2/show/NCT02215096
								Guy's and St Thomas' NHS Foundation Trust	Guy's Hospital	Dr Debashis Sarker	askOHCT@gstt.nhs.uk	
Squamous cell Cancer of the Head and Neck	T4 Immunotherapy	Interventional	Phase I Trial: T4 Immunotherapy of Head and Neck Cancer	Phase I Trial: T4 Immunotherapy of Head and Neck Cancer	Yes	19183	Dr John Maher	Guy's and St Thomas' NHS Foundation Trust	Guy's Hospital	Dr John Maher	askOHCT@gstt.nhs.uk	http://public.ukcrn.org.uk/search/StudyDetail.aspx?StudyID=19183
Melanoma, Breast, Head and Neck, Lymphoma	Immunogenic	Interventional	Lytix C12-315-03	A Phase I, Open-label, Multi-centre, Multi-dose, Dose Escalation Study of LTX-315 in Patients With Transdermally Accessible Tumours	No		Dr James Spicer	Guy's and St Thomas' NHS Foundation Trust	Guy's Hospital	Dr James Spicer	askOHCT@gstt.nhs.uk	https://clinicaltrials.gov/ct2/show/NCT01986426
								University College London Hospital	Dr Rebecca Kristeleit	hazel.muteweri@uclh.nhs.uk		
Solid tumours: Breast, gastric, urothelial and endometrial tumours	Targeted chemotherapy, SYD985	Interventional	First-in-human Study With the Antibody-drug Conjugate SYD985 to Evaluate Safety and Efficacy in Cancer Patients	A two part first-in-human phase I study (with expanded cohorts) with the antibody-drug conjugate SYD985 to evaluate the safety, pharmacokinetics and efficacy in patients with locally advanced or metastatic solid tumours	No		Dr Udai Banerji	The Royal Marsden NHS Foundation Trust	Royal Marsden Hospital	Dr Udai Banerji	udai.banerji@icr.ac.uk	https://clinicaltrials.gov/ct2/show/NCT02277717
Breast, Colorectal, Head and Neck, Non-small cell lung, liver, oesophagus, pancreas, melanoma	PDL-1 inhibitor	Interventional	Phase 1/2 study of MEDI4736 in Subjects With Advanced Solid Tumours	Phase 1/2 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4736 in Subjects with Advanced Solid Tumours	Yes	15886	Prof David Cunningham	The Royal Marsden NHS Foundation Trust	Royal Marsden Hospital	Prof David Cunningham	David.Cunningham@rmh.nhs.uk	http://public.ukcrn.org.uk/Search/StudyDetail.aspx?StudyID=15886
								Sarah Cannon Research Centre			SCRI referral form	
Solid tumours, HCC	FGFR4 antibody	Interventional	A Phase I, Open-Label,Two-Part, Safety and Tolerability Study of U3-1784 in Patients with Advanced Solid Tumours	A Phase I, Open-Label,Two-Part, Safety and Tolerability Study of U3-1784 in Patients with Advanced Solid Tumours	Pending		Prof Jeff Evans	The Royal Marsden NHS Foundation Trust	Royal Marsden Hospital	Dr Juanita Lopez	Juanita.Lopez@icr.ac.uk	https://clinicaltrials.gov/ct2/show/NCT02690350
								Guy's and St Thomas'	Guy's Hospital	Dr Debashis Sarker	askOHCT@gstt.nhs.uk	

LONDON ONCOLOGY CLINICAL TRIALS DIRECTORY

PHASE I STUDIES												
Cancers	Drug	Study Type	Short Name	Name of Study	NIHR adopted?	UKCRN ID	Chief Investigator	Trust	Hospital	Principal Investigator	Contact	Inclusion/Exclusion
Non-small cell lung, prostate, melanoma, bladder	Coxsackievirus (CVA21)	Interventional	STORM	STORM - A Phase 1, Dose-Finding and Signal-Seeking Study of the Safety and Efficacy of intravenous CAVATAK (coxsackievirus A21, CVA21) Alone and in Combination with Cytotoxic Therapy in Patients with Late Stage Solid Tumours (NSCLC, Castrate-Resistant Prostate Cancer, Melanoma and Bladder Cancer)	No		Prof Hardev Pandha	The Royal Marsden NHS Foundation Trust	Royal Marsden Hospital	Prof Kevin Harrington	Rachel.Starkings@rmh.nhs.uk	https://clinicaltrials.gov/ct2/show/NCT02043665
Ovary, cervix, endometrium, bladder, CRPC, oesophagus, NSCLC	HuMax-TF-ADC	Interventional	HuMax®-TF-ADC Safety Study in Patients With Solid Tumors	First-in-human, Dose-escalating Safety Study of Tissue Factor Specific Antibody Drug Conjugate (HuMax® TF ADC) in Patients With Locally Advanced and/or Metastatic Solid Tumors Known to Express Tissue Factor	No		Prof Johann De Bono	The Royal Marsden NHS Foundation Trust	Royal Marsden Hospital	Prof Johann De Bono	Johann.DeBono@icr.ac.uk	https://clinicaltrials.gov/ct2/show/NCT02001623
								Guy's and St Thomas' NHS Foundation Trust	Guy's Hospital	Dr James Spicer	askOHCT@gstt.nhs.uk	
Triple negative breast cancer, gastric, pancreatic, small cell lung, bladder, ovarian cancer	PD-1 inhibitors	Interventional	NCRN - 2808 CheckMate032 Nivolumab combined with Ipilimumab in Solid Tumours	CheckMate032: A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumours	Yes	15842	Prof Jeff Evans	Royal Marsden Hospital NHS Foundation Trust	Royal Marsden Hospital	Dr Ian Chau	Ian.Chau@rmh.nhs.uk	https://clinicaltrials.gov/ct2/show/NCT01928394
Advanced Castrate-resistant Prostate Cancer (CRPC); Squamous Non-Small Cell Lung Cancer (sqNSCLC); Triple Negative Breast Cancer (TNBC)	AZD8186 (PI3K inhibitor)	Interventional	A Phase I, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD8186	A Phase I, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD8186 in Patients with Advanced Castrate-resistant Prostate Cancer (CRPC), Squamous Non-Small Cell Lung Cancer (sqNSCLC), Triple Negative Breast Cancer (TNBC) and Patients with Known PTEN-deficient Advanced Solid Malignancies, with Expansion to Assess the Pharmacodynamic Activity of AZD8186 within Prospectively-validated PTEN-deficient Tumours	No		Prof Johann De Bono	The Royal Marsden NHS Foundation Trust	Royal Marsden Hospital	Prof Johann De Bono	Johann.DeBono@icr.ac.uk	https://clinicaltrials.gov/ct2/show/NCT01884285
Advanced peritoneal mesothelioma or non-squamous NSCLC Stage III/IV, Metastatic Uveal Melanoma, HCC, Glioma	ADI-PEG 20 (pegylated arginine deiminase)	Interventional	NCRN - 3003: TRAP - study in subjects with MPM, PM or NSCLC	Phase 1 Study in Subjects with Tumors Requiring Arginine to Assess ADI-PEG 20 with Pemetrexed and Cisplatin (ADIPemCis) (TRAP Study)	Yes	16346	Dr Peter Szlosarek	Guy's and St Thomas' NHS Foundation Trust	Guy's Hospital	Dr James Spicer	askOHCT@gstt.nhs.uk	https://clinicaltrials.gov/ct2/show/NCT02029690
								Barts Health NHS Trust	Bart's Cancer Institute	Dr Peter Szlosarek	p.w.szlosarek@qmul.ac.uk	
stage IV recurrent metastatic squamous NSCLC or recurrent MPM	GSK3052230 (FGFR1 inhibitor)	Interventional	Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling	Multi-arm, Non-randomized, Open-Label Phase IB Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated FGF Pathway Signaling	No			Guy's and St Thomas' NHS Foundation Trust	Guy's Hospital		askOHCT@gstt.nhs.uk	https://www.clinicaltrials.gov/show/NCT01868022
								Sarah Cannon Research Institute UK			SCRI Referral Form	
NSCLC	Pembrolizumab (PD1 Antibody)	Interventional	Pembrolizumab and Palliative Radiotherapy in Lung (PEAR)	Phase I Dose Escalation of pAlliative Radiotherapy With Anti-PD1 Antibody Pembrolizumab in Thoracic Tumours	No		Dr Merina Ahmed	The Royal Marsden NHS Foundation Trust	Royal Marsden Hospital	Dr Merina Ahmed	Merina.Ahmed@rmh.nhs.uk	https://clinicaltrials.gov/ct2/show/NCT02587455
Melanoma	MLN2480 (pan Raf inhibitor)	Interventional	MLN2480	An Open-Label, Phase 1, Dose Escalation Study of MLN2480 in Patients With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion Phase in Patients With Metastatic Melanoma	No		Prof Mark Middleton	The Royal Marsden NHS Foundation Trust	Royal Marsden Hospital	Dr Martin Gore	Martin.Gore@rmh.nhs.uk	https://clinicaltrials.gov/ct2/show/NCT01425008

LONDON ONCOLOGY CLINICAL TRIALS DIRECTORY

PHASE I STUDIES												
Cancers	Drug	Study Type	Short Name	Name of Study	NIHR adopted?	UKCRN ID	Chief Investigator	Trust	Hospital	PrincipallInvestigator	Contact	Inclusion/Exclusion
Gastric, gastroesophageal junction adenocarcinoma, NSCLC, Transitional cell carcinoma of urothelium	VEGF-2 and PD-1 inhibitor	Interventional	A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC or Transitional Cell Carcinoma of the Urothelium	An Open-Label, Multicenter, Phase 1 Study of Ramucirumab Plus Pembrolizumab in Patients With Locally Advanced and Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma, Non-Small Cell Lung Cancer, or Transitional Cell Carcinoma of the Urothelium	No		Dr Ian Chau	The Royal Marsden NHS Foundation Trust	Royal Marsden Hospital	Dr Ian Chau	Ian.Chau@rmh.nhs.uk	https://www.clinicaltrials.gov/ct2/show/NCT02443324
								Sarah Cannon Research Institute UK			SCRI Referral Form	
Anal carcinoma, biliary adenocarcinoma, neuroendocrine tumours, endometrial, cervical, vulvar carcinomas, small cell lung carcinoma, mesothelioma, thyroid carcinoma, salivary gland carcinoma	Pembrolizumab (PD1 Antibody)	Interventional	KEYNOTE 158	A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors (KEYNOTE 158)	No		Dr Timothy Yap	The Royal Marsden NHS Foundation Trust	Royal Marsden Hospital	Dr Timothy Yap	timothy.yap@icr.ac.uk	https://clinicaltrials.gov/ct2/show/NCT02628067
Advanced Bladder cancer	PD1 Antibody	Interventional	Pembrolizumab in Muscle Invasive/Metastatic Bladder Cancer (PLUMMB)	Phase I Study of Hypofractionated Radiotherapy and Anti-PD1 Antibody (Pembrolizumab) in the Treatment of Advanced Bladder Cancer	No		Dr Alison Tree	The Royal Marsden NHS Foundation Trust	Royal Marsden Hospital	Dr Alison Tree	alison.tree@rmh.nhs.uk	https://clinicaltrials.gov/ct2/show/NCT02560636
Untreated Renal Cell Cancer	PDL-1 antibody, TK inhibitor	Interventional	A Study Of Avelumab In Combination With Axitinib In Advanced Renal Cell Cancer (JAVELIN Renal 100)	A Phase 1b, Open-Label, Dose-Finding Study To Evaluate Safety, Pharmacokinetics And Pharmacodynamics Of Avelumab (MSB0010718C) In Combination With Axitinib (AG-013736) In Patients With Previously Untreated Advanced Renal Cell Cancer	No		Dr James Larkin	The Royal Marsden NHS Foundation Trust	Royal Marsden Hospital	Dr James Larkin	James.Larkin@rmh.nhs.uk	https://clinicaltrials.gov/ct2/show/NCT02493751
								East and North Hertfordshire NHS Trust	Mount Vernon Cancer Center			
								Barts Health NHS Trust	St Bartholomew's Hospital			
Ovarian Cancer with gBRCA mutation	PARP inhibitor	Interventional	A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II)	A Phase I/II, Open-Label, Safety, Pharmacokinetic, and Preliminary Efficacy Study of Oral Rucaparib in Patients With gBRCA Mutation Ovarian Cancer or Other Solid Tumor	No		Dr Sarah Blagden	The Royal Marsden NHS Foundation Trust	Royal Marsden Hospital	Dr Susana Banerjee	Michelle.Everard@rmh.nhs.uk	https://clinicaltrials.gov/ct2/show/NCT01482715
								Guy's and St Thomas' NHS Foundation Trust	Guy's Hospital	Dr Anna Montes	askOCHT@gstt.nhs.uk	
								Imperial College Healthcare NHS Trust	Hammersmith Hospital	Prof Hani Gabra	Hammersmith.Cancertrials@imperial.nhs.uk	
NUT midline carcinoma and solid tumours	BET inhibitor	Interventional	A phase I/II open-label, dose escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in subjects with NUT midline carcinoma (NMC) and other cancers.	A phase I/II open-label, dose escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in subjects with NUT midline carcinoma (NMC) and other cancers.	No		Prof Johann De Bono	The Royal Marsden NHS Foundation Trust	Royal Marsden Hospital	Prof Johann De Bono	Johann.DeBono@icr.ac.uk	https://clinicaltrials.gov/ct2/show/NCT01587703
Unresectable GIST	BLU-285 (PDGFRα inhibitor)		A Phase 1 Study of BLU-285 in Patients with Gastrointestinal Stromal Tumors (GIST) and other Relapsed and Refractory Solid Tumors	A Phase 1 Study of BLU-285 in Patients with Gastrointestinal Stromal Tumors (GIST) and other Relapsed and Refractory Solid Tumours	Yes		Dr Robin Jones	The Royal Marsden NHS Foundation Trust	Royal Marsden Hospital	Dr Robin Jones	Robin.Jones@icr.ac.uk	https://clinicaltrials.gov/ct2/show/NCT02508532
Grade IV glioblastoma	PARP inhibitor	Interventional	Olaparib and Temozolomide in Treating Patients With Relapsed Glioblastoma	A Cancer Research UK Phase I Trial of Olaparib (AZD2281), an Oral PARP Inhibitor, in Combination With Extended Low-Dose Oral Temozolomide in Patients With Relapsed Glioblastoma	No		Prof Anthony Chalmers	The Royal Marsden NHS Foundation Trust	Royal Marsden Hospital	Dr Juanita Lopez	Juanita.Lopez@icr.ac.uk	https://clinicaltrials.gov/ct2/show/NCT01390571
Solid tumour and lymphoma	VX-803 (ATR inhibitor)	Interventional	REFMAL 385	An Open-Label Study of the Safety, Tolerability, and Pharmacokinetic/ Pharmacodynamic Profile of VX-803 as a Single Agent and in Combination With Carboplatin in Subjects With Advanced Solid Tumors or Lymphoma	Pending		Prof Johann De Bono	The Royal Marsden NHS Foundation Trust	Royal Marsden Hospital	Prof Johann De Bono	Johann.DeBono@icr.ac.uk	https://clinicaltrials.gov/ct2/show/NCT02278250
								Sarah Cannon Research Insitute			SCRI Referral Form	

LONDON ONCOLOGY CLINICAL TRIALS DIRECTORY

PHASE I STUDIES												
Cancers	Drug	Study Type	Short Name	Name of Study	NIHR adopted?	UKCRN ID	Chief Investigator	Trust	Hospital	Principal Investigator	Contact	Inclusion/Exclusion
Solid tumour and lymphoma	MPDL3280A (PDL1 antibody)	Interventional	An Early-Phase, Multicenter, Open-Label Study of the Safety and Pharmacokinetics of Anti-Pd-L1 Antibody (MPDL3280A) in Pediatric and Young Adult Patients with Previously Treated Solid Tumors	An Early-Phase, Multicenter, Open-Label Study of the Safety and Pharmacokinetics of Anti-Pd-L1 Antibody (MPDL3280A) in Pediatric and Young Adult Patients with Previously Treated Solid Tumors	Yes	18668	Dr Lynley Marshall	The Royal Marsden NHS Foundation Trust	Royal Marsden Hospital	Dr Lynley Marshall	Lynley.Marshall@icr.ac.uk	https://clinicaltrials.gov/ct2/show/NCT02541604
B-cell and follicular lymphoma	GSK2816126 (EZH2 inhibitor)	Interventional	GSK2816126 in B-cell and follicular lymphoma	A Phase I Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell and Transformed Follicular Lymphoma	No		Prof Peter Johnson	The Royal Marsden NHS Foundation Trust	Royal Marsden Hospital	Dr Timothy Yap	timothy.yap@icr.ac.uk	https://clinicaltrials.gov/ct2/show/NCT02082977
Chronic Lymphocytic Leukaemia	ACP-196 (BTK inhibitor)	Interventional	ACP-196 (ACE-CL-001)	A Phase 1, Multicenter, Open-label, and Dose-escalation Study of ACP-196 in Subjects With Chronic Lymphocytic Leukemia	No		Prof Peter Hillmen	King's College Hospital NHS Foundation Trust	King's College Hospital	Dr James Spicer	donna.yarde@gstt.nhs.uk	https://clinicaltrials.gov/ct2/show/NCT02029443
ALK/TRK positive Solid Tumours	TSR-011 (ALK/TRK inhibitor)	Interventional	TSR-011	A Phase I/IIa Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced Solid Tumors and Lymphomas	No			Sarah Cannon Research Institute			SCRI Referral Form	https://clinicaltrials.gov/ct2/show/NCT02048488
Chronic Lymphocytic Leukaemia	NA	Observational	CLARITY	Clinical validation of biomarkers that determine Resistance to BTK inhibition with Ibrutinib in Mantle Cell Lymphoma and Chronic Lymphocytic Leukaemia	No		Dr Sunil Iyengar	The Royal Marsden NHS Foundation Trust	Royal Marsden Hospital	Dr Sunil Iyengar	Sunil.Iyengar@rmh.nhs.uk	http://www.ukctg.nhs.uk/trialdetails/NCT02267590
Non-Hodgkin's Lymphoma and Solid Tumours with PI3KCA or PTEN alteration	PI3K inhibitor	Interventional	Copanlisib Pharmacodynamic Study	A Phase I Pharmacodynamic Study of Copanlisib (BAY 80-6946) as Monotherapy in Patients With Non-Hodgkin's Lymphoma and Solid Tumors	No		Prof David Cunningham	The Royal Marsden NHS Foundation Trust	Royal Marsden Hospital	Prof David Cunningham	David.Cunningham@rmh.nhs.uk	https://www.clinicaltrials.gov/ct2/show/NCT02155582
Advanced Squamous Cell Carcinoma of Head and Neck	PARP inhibitor	Interventional	Phase I Study of Olaparib Combined With Cisplatin-based Chemoradiotherapy to Treat Locally Advanced Head and Neck Cancer (ORCA-2)	A Phase I Trial of Olaparib in Addition to Cisplatin-based Concurrent Chemoradiotherapy for Patients With High Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck (NHSCC)	No		Dr Martin Forster	The Royal Marsden NHS Foundation Trust	Royal Marsden Hospital	Kevin Harrington	Rachel.Starkings@rmh.nhs.uk	https://clinicaltrials.gov/ct2/show/NCT02308072
								University College London Hospitals NHS Foundation Trust	University College London Hospital	Dr Martin Forster	martin.forster@uclh.nhs.uk	
								Guy's and St Thomas' NHS Foundation Trust	Guy's Hospital	Teresa Guerrero-Urbano	askOHCT@gstt.nhs.uk	
Non-haematological malignancies	Oral A-, B-, and CRAF inhibitor and mTORC1/2 inhibitor, or Aurora A Kinase Inhibitor	Interventional	A Phase 1B Study of MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Patients With Advanced Nonhematologic Malignancies	A Multiarm, Open-label, Phase 1b Study of MLN2480 (an Oral A-, B-, and CRAF Inhibitor) in Combination With MLN0128 (an Oral mTORC 1/2 Inhibitor), or Alisertib (an Oral Aurora A Kinase Inhibitor), or Paclitaxel, or Cetuximab, or Irinotecan, in Adult Patients With Advanced Nonhematologic Malignancies	No			Sarah Cannon Research Institute UK			SCRI Referral Form	https://www.clinicaltrials.gov/ct2/show/NCT02327169
Advanced Multiple myeloma	NF-kB downstream pathway inhibitor	Interventional	Phase I/IIa Study of DTP3 in Patients With Advanced Multiple Myeloma	A Phase I/IIa Dose Escalation and Subsequent Cohort Expansion Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Efficacy of Intravenous DTP3 in Patients with Relapsed or Refractory Multiple Myeloma	Yes	20451	Prof Jane Apperley	Imperial College Healthcare NHS Trust	Hammersmith Hospital	Prof Jane Apperley	Laura.Eshmene@imperial.nhs.uk	http://public.ukcrn.org.uk/Search/StudyDetail.aspx?StudyID=20451
Solid Tumours or Multiple Myeloma	TAS-120 (FGFR inhibitor)	Interventional	TAS-120	A Dose-Finding Phase 1 Study of TAS-120 in Patients With Advanced Solid Tumors With or Without Fibroblast Growth Factor/Receptor (FGF/FGFR)-Related Abnormalities Followed By A Phase 2 Study in Patients With Advanced Solid Tumors or Multiple Myeloma With FGF/FGFR-Related Abnormalities	No		Dr Tobias Arkenau	Sarah Cannon Research Institute		Dr Tobias Arkenau	SCRI Referral Form	https://www.clinicaltrials.gov/ct2/show/NCT02052778
Solid Tumours (BRAF, KRAS, NRAS mutations) and Multiple Myeloma	RAF/MEK inhibitor	Interventional	Phase I Trial of ROS126766 (DDU RAF/MEK)	A Phase I Trial of ROS126766 (a Dual RAF/MEK Inhibitor) Exploring Intermittent, Oral Dosing Regimens in Patients With Solid Tumours or Multiple Myeloma	No		Dr Udai Banerji	The Royal Marsden NHS Foundation Trust	Royal Marsden Hospital	Dr Udai Banerji	Udai.Banerji@rmh.nhs.uk	https://clinicaltrials.gov/ct2/show/NCT02407509

LONDON ONCOLOGY CLINICAL TRIALS DIRECTORY

PHASE I STUDIES												
Cancers	Drug	Study Type	Short Name	Name of Study	NIHR adopted?	UKCRN ID	Chief Investigator	Trust	Hospital	Principal Investigator	Contact	Inclusion/Exclusion
Solid tumours, including metastatic melanoma	pan-RAF inhibitor	Interventional	A Phase I, First in Man Study to Evaluate the Safety and Tolerability of a panRAF Inhibitor (CCT3833/BAL3833) in Patients With Solid Tumours (PanRAF)	A Phase 1, First in Man, Dual Centre, Open-label Dose Escalation Study With Expansion to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CCT3833 (BAL3833), a panRAF Inhibitor, Given Orally in Patients With Advanced Solid Tumours, Including Metastatic Melanoma	No		Dr James Larkin	The Royal Marsden NHS Foundation Trust	Royal Marsden Hospital	Dr Udai Banerji	Udai.Banerji@icr.ac.uk	https://clinicaltrials.gov/ct2/show/NCT02437227
Solid Tumour expressing FRα	FRα antibody	Interventional	This First in Human Study of the New Therapeutic Antibody MOv18 IgE in Patients With Advanced Cancer	A Cancer Research UK Phase I Study of MOv18 IgE, a First in Class Chimeric IgE Antibody Against Folate Receptor-α, in Patients With Advanced Solid Tumours	No		Dr James Spicer	Guy's and St Thomas' NHS Foundation Trust	Guy's Hospital	Dr James Spicer	askOHCT@gstt.nhs.uk	https://clinicaltrials.gov/ct2/show/NCT02546921
								The Royal Marsden NHS Foundation Trust	Royal Marsden Hospital	Dr Udai Banerji	Udai.Banerji@icr.ac.uk	
Solid Tumours	Vaccination with hTERT peptides	Interventional	The VAPER Trial	In vivo generation of optimal tumour antigen-specific anticancer immune responses, by vaccination with human telomerase reverse transcriptase (hTERT) peptides, in combination with specific adjuvants and elimination of immunosuppressive regulatory cells, in patients with advanced cancer (VAPER: Phase 1 Pilot study)	No		Dr James Spicer	Guy's and St Thomas' NHS Foundation Trust	Guy's Hospital	Dr James Spicer	askOHCT@gstt.nhs.uk	http://www.hra.nhs.uk/news/research-summaries/vaccination-with-adjuvants-peptides-elimination-of-regulatory-cells/
Solid Tumours	Axitinib (TK inhibitor), Crizotinib (ALK1 and ROS1 inhibitor)	Interventional	A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumours	A Phase 1b, Open Label, Dose Escalation Study To Evaluate Safety, Pharmacokinetics And Pharmacodynamics Of Axitinib (AG-013736) In Combination With Crizotinib (PF-02341066) In Patients With Advanced Solid Tumours	No		Dr James Larkin	The Royal Marsden NHS Foundation Trust	Royal Marsden Hospital	Dr James Larkin	James.Larkin@rmh.nhs.uk	https://clinicaltrials.gov/ct2/show/NCT01999972
								Barts Health NHS Trust	St Bartholomew's Hospital			
Solid Tumours	TVB-2640 (FASN inhibitor)	Interventional	A Phase 1, First-In-Human Study of Escalating Doses of Oral TVB-2640 in Patients With Solid Tumours	A Phase 1, First-In-Human Study of Escalating Doses of Oral TVB-2640 in Patients With Solid Tumours	No		Dr Tobias Arkenau	Sarah Cannon Research Institute UK			SCRI Referral Form	https://www.clinicaltrials.gov/ct2/show/NCT0223247
								The Royal Marsden NHS Foundation Trust	Royal Marsden Hospital	Dr Juanita Lopez	Juanita.Lopez@icr.ac.uk	
Solid Tumours	Avelumab (PD-L1 inhibitor)	Interventional	Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)	A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of Avelumab (MSB0010718C) in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications	No			Sarah Cannon Research Institute UK			SCRI Referral Form	https://www.clinicaltrials.gov/ct2/show/NCT01772004
Solid Tumours	GSK2256098 (FAK inhibitor) and Trametinib (MEK inhibitor)	Interventional	A Dose Escalation Study to Assess Safety of GSK2256098 (FAK Inhibitor) in Combination With Trametinib (MEK Inhibitor) in Subjects With Advanced Solid Tumours	A Phase 1b, Multi-center, Open-label, Dose Escalation Study of GSK2256098 (FAK Inhibitor) in Combination With Trametinib (MEK Inhibitor) in Subjects With Advanced Solid Tumours	No			Sarah Cannon Research Institute UK			SCRI Referral Form	https://www.clinicaltrials.gov/show/NCT01938443
								Imperial College Healthcare NHS Trust	Hammersmith Hospital	Dr Sarah Blagden	Hammersmith.Cancertrials@imperial.nhs.uk	
Solid tumours	AT13148 (AGC kinase inhibitor)	Interventional	Phase I study of AT13148, a novel AGC kinase inhibitor	A Cancer Research UK Phase I first in man study of the novel AGC kinase inhibitor AT13148 given orally in patients with advanced solid tumours	Yes	11846	Dr Udai Banerji	Royal Marsden NHS Foundation Trust	Royal Marsden Hospital	Dr Udai Banerji	Udai.Banerji@rmh.nhs.uk	http://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-of-at13148-for-advanced-solid-tumours
Solid Tumours	Artemether	Interventional	LON002-002	A Phase 1/2a Study of LON002 (Sublingual Artemether Spray) in Subjects With Advanced Solid Tumours.	No		Dr Debashis Sarker	Guy's and St Thomas' NHS Foundation Trust	Guy's Hospital	Dr Debashis Sarker	askOHCT@gstt.nhs.uk	https://clinicaltrials.gov/ct2/show/NCT02263950
Solid Tumours	Artemether	Interventional	LON002-003	An Extension Study of LON002 in Patients With Cancer	No		Dr Debashis Sarker	Guy's and St Thomas' NHS Foundation Trust	Guy's Hospital	Dr Debashis Sarker	askOHCT@gstt.nhs.uk	https://clinicaltrials.gov/ct2/show/NCT02390986
Solid Tumours	PI3K inhibitors	Interventional	PIPA	PIPA: A Phase 1b study to assess the safety, tolerability and efficacy of the PI3K inhibitors, taselisib (GDC-0032) or pictilisib (GDC-0941), in combination with Palbociclib, with the subsequent addition of fulvestrant in PIK3CA-mutant breast cancers.	No		Dr Nick Turner	Royal Marsden NHS Foundation Trust	Royal Marsden Hospital	Dr Tim Yap	timothy.yap@icr.ac.uk	https://clinicaltrials.gov/show/NCT02389842
Solid Tumours	PARP and AKT inhibitors	Interventional	ComPAKT: A Phase I trial of olaparib in combination with AZD5363	ComPAKT: A Phase I multicentre trial of the combination of olaparib (PARP inhibitor) and AZD5363 (AKT inhibitor) in patients with advanced solid tumours	Yes	16550	Dr Timothy Yap	The Royal Marsden NHS Foundation Trust	Royal Marsden Hospital	Dr Timothy Yap	timothy.yap@icr.ac.uk	http://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-looking-at-olapirib-and-AZD5363-people-cancer-come-back-spread-elsewhere-body-compakt

LONDON ONCOLOGY CLINICAL TRIALS DIRECTORY

PHASE I STUDIES												
Cancers	Drug	Study Type	Short Name	Name of Study	NIHR adopted?	UKCRN ID	Chief Investigator	Trust	Hospital	Principal Investigator	Contact	Inclusion/Exclusion
Solid tumour, lymphoma	Notch inhibitor	Interventional	NOTCH	A Phase 1 Study of LY3039478 in Patients With Advanced or Metastatic Cancer	No		Dr Debashis Sarker	King's College Hospital	King's College Hospital	Dr Debashis Sarker	askOHCT@gstt.nhs.uk	https://clinicaltrials.gov/ct2/show/NCT01695005
Solid Tumours, Lymphoma	MCT1 inhibitor	Interventional	A Phase I trial of AZD3965 in patients with advanced cancer	A Cancer Research United Kingdom Phase I Trial of AZD3965, a Monocarboxylate Transporter 1 Inhibitor (MCT1) in Patients With Advanced Cancer	Yes	13474	Prof Ruth Plummer	The Royal Marsden NHS Foundation Trust	Royal Marsden Hospital	Dr Udai Banerji	Udai.Banerji@rmh.nhs.uk	http://public.ukcrn.org.uk/Search/StudyDetail.aspx?StudyID=13474
Solid Tumours	mTORC1/2 inhibitor	Interventional	TAXTORC	TAXTORC: A Phase I multi-centre trial of the combination of AZD2014 (dual TORC1 and TORC2 inhibitor) and weekly paclitaxel in patients with solid tumours	Yes	14484	Dr Udai Banerji	The Royal Marsden NHS Foundation Trust Guy's and St Thomas' NHS Foundation Trust	Royal Marsden Hospital Guy's Hospital	Dr Udai Banerji Dr James Spicer	Udai.Banerji@rmh.nhs.uk askOHCT@gstt.nhs.uk	http://public.ukcrn.org.uk/Search/StudyDetail.aspx?StudyID=14484
Solid Tumours	sphingomyelin synthase activator	Interventional	MIN-001-1203: 2-OHOA in advanced solid tumours, v1.0	A Phase 1/2A Dose Escalation Study of 2-hydroxyoleic Acid (2-OHOA; Minerval*) in Adult Patients With Advanced Solid Tumours Including Malignant Glioma	No		Prof Johann De Bono	The Royal Marsden NHS Foundation Trust	Royal Marsden Hospital	Prof Johann De Bono	Johann.DeBono@icr.ac.uk	https://clinicaltrials.gov/ct2/show/NCT01792310
Solid Tumours	MLN0128 (mTORC1/2 inhibitor), MLN1117 (PI3Kα Inhibitor)	Interventional	Phase 1b Study of MLN0128 in Combination With MLN1117 in Adult Patients With Advanced Nonhematologic Malignancies	A Multicenter, Open-label, Phase 1b Study of MLN0128 (an Oral mTORC1/2 Inhibitor) in Combination With MLN1117 (an Oral PI3Kα Inhibitor) in Adult Patients With Advanced Nonhematologic Malignancies	No		Dr Juanita Lopez	The Royal Marsden NHS Foundation Trust	Royal Marsden Hospital	Dr Juanita Lopez	Juanita.Lopez@icr.ac.uk	https://clinicaltrials.gov/ct2/show/NCT01899053
Solid Tumours and Lymphoma	ONX-0801 (α-folate Receptor inhibitor)	Interventional	A Phase I trial of ONX-0801	A Phase I Trial of ONX-0801 (a Novel α-folate Receptor-mediated Thymidylate Synthase Inhibitor) Exploring Once Weekly and Alternate Week Dosing Regimens in Patients With Solid Tumours	No		Dr Udai Banerji	The Royal Marsden NHS Foundation Trust	Royal Marsden Hospital	Dr Udai Banerji	Udai.Banerji@rmh.nhs.uk	https://clinicaltrials.gov/ct2/show/NCT02360345
Solid Tumours	Olaparib (Parp inhibitor)	Interventional	Study to Assess the Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver Impairment	An Open-label, Non-randomised, Multicentre, Comparative, Phase I Study to Determine the Pharmacokinetics, Safety and Tolerability of Olaparib Following a Single Oral 300 mg Dose to Patients With Advanced Solid Tumours and Normal Hepatic Function or Mild or Moderate Hepatic Impairment	No		Dr Rhoda Molfie	The Royal Marsden NHS Foundation Trust	Royal Marsden Hospital	Dr Juanita Lopez	Juanita.Lopez@icr.ac.uk	https://clinicaltrials.gov/ct2/show/NCT01894243
Solid Tumours, Lymphoma	VS-5584 (PI3K/mTOR Inhibitor)	Interventional	Phase I Dose Escalation Study of VS-5584 in Subjects With Advanced Non-Hematologic Malignancies or Lymphoma	A Phase I Dose Escalation Study of VS-5584, a Dual PI3K/mTOR Inhibitor, in Subjects With Advanced Non-Hematologic Malignancies or Lymphoma	No		Dr Udai Banerji	The Royal Marsden NHS Foundation Trust	Royal Marsden Hospital	Dr Udai Banerji	Udai.Banerji@rmh.nhs.uk	https://clinicaltrials.gov/ct2/show/NCT01991938
Solid Tumours	VX-970 (ATR inhibitor)	Interventional	An Open-Label, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics of VX-970 in Combination With Cytotoxic Chemotherapy	An Open-Label, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics of VX-970 in Combination With Cytotoxic Chemotherapy in Subjects With Advanced Solid Tumors	No		Prof Johann De Bono	The Royal Marsden NHS Foundation Trust Sarah Cannon Research Institute UK	Royal Marsden Hospital	Dr Timothy Yap	timothy.yap@icr.ac.uk SCRI Referral Form	https://clinicaltrials.gov/ct2/show/NCT02157792
BRAF V600 Mutation Positive Tumours	GSK2118436 (B-raf inhibitor)	Interventional	A Pharmacokinetics (PK) Study of the Effects of Rabeprazole and Rifampin on Dabrafenib in Subjects With BRAF V600 Mutation Positive Tumours	An Open-label Study to Evaluate the Effects of a Potent CYP3A4 Inducer and the Effects of a pH Elevating Agent on the Repeat Dose Pharmacokinetics of Dabrafenib (GSK2118436) in Subjects With BRAF V600 Mutation Positive Tumours	No			Sarah Cannon Research Institute UK			SCRI Referral Form	https://www.clinicaltrials.gov/show/NCT01954043
Solid Tumours	AZD6738 (ATR inhibitor)	Interventional	Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents	A Modular Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of AZD6738 in Combination With Cytotoxic Chemotherapy and/or DNA Damage Repair/Novel Anti-cancer Agents in Patients With Advanced Solid Malignancies	No		Dr Saeed Rafii	The Royal Marsden NHS Foundation Trust	Royal Marsden Hospital	Dr Timothy Yap	timothy.yap@icr.ac.uk	https://clinicaltrials.gov/ct2/show/NCT02264678
Solid tumours	AZD5363 (AKT inhibitor)	Interventional	A Phase I, Open Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD5363 under Adaptable Dosing Schedules in Patients with Advanced Solid Malignancies	A Phase I, Open Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD5363 under Adaptable Dosing Schedules in Patients with Advanced Solid Malignancies	No		Dr Udai Banerji	The Royal Marsden NHS Foundation Trust	Royal Marsden Hospital	Dr Udai Banerji	Udai.Banerji@rmh.nhs.uk	https://clinicaltrials.gov/ct2/show/NCT01226316

LONDON ONCOLOGY CLINICAL TRIALS DIRECTORY

PHASE I STUDIES												
Cancers	Drug	Study Type	Short Name	Name of Study	NIHR adopted?	UKCRN ID	Chief Investigator	Trust	Hospital	Principal Investigator	Contact	Inclusion/Exclusion
Solid tumours	BAL101553 (Microtubule destabiliser)	Interventional	An open-label Phase 1/2a study of oral BAL101553 in adult patients with advanced solid tumours	An open-label Phase 1/2a study of oral BAL101553 in adult patients with advanced solid tumours	No		Dr Rebecca Kristeleit	The Royal Marsden NHS Foundation Trust	Royal Marsden Hospital	Dr Juanita Lopez	Juanita.Lopez@icr.ac.uk	https://clinicaltrials.gov/ct2/show/NCT02490800
								University College London NHS Foundation Trust	University College London Hospital	Dr Rebecca Kristeleit	r.kristeleit@ucl.ac.uk	
Solid tumours	TAS-119 (Aurora A inhibitor)	Interventional	A phase 1, open-label, non-randomized, dose escalating safety, tolerability, pharmacokinetic, and pharmacodynamic study of tas-119, as monotherapy and in combination with docetaxel, in patients with advanced solid tumours	A phase 1, open-label, non-randomized, dose escalating safety, tolerability, pharmacokinetic, and pharmacodynamic study of tas-119, as monotherapy and in combination with docetaxel, in patients with advanced solid tumours	No		Prof Johann De Bono	The Royal Marsden NHS Foundation Trust	Royal Marsden Hospital	Prof Johann De Bono	Johann.DeBono@icr.ac.uk	https://clinicaltrials.gov/ct2/show/NCT02448589
Solid tumours	BAY 1143269 (MKNK1 inhibitor)	Interventional	An open-label, non-randomized, multicenter Phase I study to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, and maximum tolerated dose of oral MKNK1 inhibitor BAY 1143269 given alone or in combination with intravenous docetaxel in subjects with advanced solid tumours.	An open-label, non-randomized, multicenter Phase I study to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, and maximum tolerated dose of oral MKNK1 inhibitor BAY 1143269 given alone or in combination with intravenous docetaxel in subjects with advanced solid tumours.	No		Dr Timothy Yap	The Royal Marsden NHS Foundation Trust	Royal Marsden Hospital	Dr Timothy Yap	timothy.yap@icr.ac.uk	https://clinicaltrials.gov/ct2/show/NCT02439346
Solid Tumours	AZD6738 (ATR inhibitor)	Interventional	PATRIOT	A Phase I Study to assess the Tolerability, Safety and Biological Effects of a Specific Ataxia Telangiectasia and Rad3 – related (ATR) Inhibitor (AZD6738) as a Single Agent and in Combination with Palliative Radiation Therapy in Patients with Solid Tumours	Yes	17568	Prof Kevin Harrington	Guy's and St Thomas' NHS Foundation Trust	Guy's Hospital	Dr James Spicer	askOCT@gstt.nhs.uk	http://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-looking-AZD6738-radiotherapy-advanced-solid-tumours-patriot
								The Royal Marsden NHS Foundation Trust	Royal Marsden Hospital	Prof Kevin Harrington	Rachel.Starkings@rmh.nhs.uk	
Paediatrics, BRAF mutations	Dabrafenib (B-raf inhibitor)	Interventional	NCRN511 - Dabrafenib in paediatric BRAF solid tumours	Phase I/IIa, 2-Part, Multi-Center, Single-Arm, Open-Label Study to Determine the Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib in Pediatric Subjects Aged 1 Month to <18 Years with Advanced BRAF V600-Mutation Positive Solid Tumors	Yes	13377	Prof Andrew Pearson	The Royal Marsden NHS Foundation Trust	Royal Marsden Hospital	Prof Andrew Pearson	Andrew.Pearson@rmh.nhs.uk	http://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-of-dabrafenib-for-children-and-teenagers-who-have-a-solid-tumour-with-a-change-to-a-gene-called-braf
Paediatrics, ALK mutations	LDK378 (ALK inhibitor)	Interventional	LDK378 in children with malignancies that have ALK alteration - CLDK378X2103	A Phase 1 open label dose escalation study of LDK378 in paediatric patients with malignancies that have a genetic alteration in anaplastic lymphoma kinase (ALK). CLDK378X2103	No		Prof Andrew Pearson	The Royal Marsden NHS Foundation Trust	Royal Marsden Hospital	Prof Andrew Pearson	Andrew.Pearson@rmh.nhs.uk	https://clinicaltrials.gov/ct2/show/NCT01742286
high grade glioma, diffuse intrinsic pontine glioma, low grade astrocytoma, neuroblastoma, ependymoma, medulloblastoma/primitive neuroectodermal tumours, rhabdomyosarcoma and/or other solid tumours with ErbB deregulation, 2-18 years old	Afinitinib (EGFR and Her2 inhibitor)	Interventional	Phase I open label, dose escalation trial to determine the MTD, safety, PK and efficacy of Afinitinib Monotherapy in children aged 2 years to <18 years with recurrent/refractory Neuroectodermal tumours, Rhabdomyosarcoma and/or other solid tumours with known ErbB pathway deregulation regardless of tumour histology.	Phase I open label, dose escalation trial to determine the MTD, safety, PK and efficacy of Afinitinib Monotherapy in children aged 2 years to <18 years with recurrent/refractory Neuroectodermal tumours, Rhabdomyosarcoma and/or other solid tumours with known ErbB pathway deregulation regardless of tumour histology.	Yes	17235	Dr Darren Hargrave	The Royal Marsden NHS Foundation Trust	Royal Marsden Hospital	Dr Lynley Marshall	Lynley.Marshall@icr.ac.uk	https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-002123-10/AT
								Great Ormond Street Hospital for Children NHS Foundation Trust	Great Ormond Street Hospital	Dr Darren Hargrave		
Solid tumour and lymphoma, 6 months to 18 years	Pembrolizumab (PD-1 antibody)	Interventional	KEYNOTE 051	A Phase I/II Study of MK3475 (Pembrolizumab) in children with advanced melanoma or a PDL1 positive advanced, relapsed refractory solid tumour or lymphoma	Yes		Prof Andrew Pearson	Great Ormond Street Hospital for Children NHS Foundation Trust	Great Ormond Street Hospital			
								The Royal Marsden NHS Foundation Trust	Royal Marsden Hospital	Dr Lynley Marshall	Lynley.Marshall@icr.ac.uk	https://clinicaltrials.gov/ct2/show/NCT02332668
Solid tumours in children and young adults, less than 21 years	Weekly nab-paclitaxel	Interventional	To Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors	A Phase 1/2, Multicenter, Open-label, Dose-finding Study to Assess the Safety, Tolerability, and Preliminary Efficacy of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent or Refractory Solid Tumors.	Yes	15227	Dr Julia Chisholm	The Royal Marsden NHS Foundation Trust	Royal Marsden Hospital	Dr Julia Chisholm	Julia.Chisholm@rmh.nhs.uk	https://clinicaltrials.gov/ct2/show/NCT01962103

LONDON ONCOLOGY CLINICAL TRIALS DIRECTORY

PHASE I STUDIES												
Cancers	Drug	Study Type	Short Name	Name of Study	NIHR adopted?	UKCRN ID	Chief Investigator	Trust	Hospital	PrincipallInvestigator	Contact	Inclusion/Exclusion
All	none	Observational	A Longitudinal Pilot Study of a Questionnaire Examining Patients' Expectations and Experiences of Participation in Phase I Anti-Cancer Clinical Drug Trials.	A Longitudinal Pilot Study of a Questionnaire Examining Patients' Expectations and Experiences of Participation in Phase I Anti-Cancer Clinical Drug Trials.	No		Dr Natalie Pattison	The Royal Marsden NHS Foundation Trust	Royal Marsden Hospital	Dr Natalie Pattison	natalie.pattison@nhs.net	
All	none	Observational	Relatives of patients on Phase 1 trials	Relatives of patients on Phase 1 trials	No		Dr Natalie Pattison	The Royal Marsden NHS Foundation Trust	Royal Marsden Hospital	Dr Natalie Pattison	natalie.pattison@nhs.net	
All	none	Observational	DDU Screening Protofol	DDU Screening Protocol - Optimising Patient Benefit From Early Clinical Trials Through Tumour Molecular Characterisation	No		Prof Johann De Bono	The Royal Marsden NHS Foundation Trust	Royal Marsden Hospital	Prof Johann De Bono	Johann.DeBono@icr.ac.uk	
All	none	Observational	DDU Patient Questionnaire	Drug Development Unit patient questionnaire assessing patients' preconceptions, expectations and motivations for phase I trials.	No		Dr Udai Banerji	The Royal Marsden NHS Foundation Trust	Royal Marsden Hospital	Dr Udai Banerji	Udai.Banerji@rmh.nhs.uk	